Скачать или смотреть Brentuximab Unveiling the Role of Anti-CD30 in Cancer Research

https://www.assaygenie.com/anti-cd30-...


Key Themes and Ideas:

Targeted Therapy: Brentuximab vedotin exemplifies precision medicine by targeting CD30, a biomarker expressed on the surface of certain lymphoma cells.
"CD30, a member of the tumor necrosis factor receptor family, is a biomarker expressed on the surface of certain lymphoma cells, making it an ideal therapeutic target for precision medicine."
The drug is specifically engineered to treat CD30-positive cancers, including Hodgkin lymphoma and anaplastic large cell lymphoma (ALCL).

Mechanism of Action: Brentuximab vedotin delivers a cytotoxic payload (monomethyl auristatin E or MMAE) directly to CD30-positive cells, inducing cell death (apoptosis) while minimizing damage to healthy tissues.
"Brentuximab vedotin works by delivering a cytotoxic agent to CD30-positive cells, inducing cell death through a targeted mechanism."

After binding to CD30, the ADC is internalized, and MMAE is released within the cell, disrupting microtubule assembly (essential for cell division).
"Upon internalization, the ADC releases its potent MMAE payload, which disrupts microtubule assembly—a critical process for cell division. This mechanism leads to apoptosis of the malignant cells while minimizing collateral damage to normal tissues, significantly reducing systemic toxicity compared to conventional chemotherapy."

Clinical Applications: Brentuximab vedotin is primarily used in managing Hodgkin lymphoma and systemic ALCL. Its use is expanding to other CD30-expressing cancers and in combination therapies.
"Brentuximab is primarily utilized in managing Hodgkin lymphoma, systemic ALCL, and other CD30-positive malignancies. It has also been studied in combination therapies for enhanced efficacy."

In Hodgkin lymphoma, it's a cornerstone treatment for relapsed or refractory cases and is being incorporated into first-line protocols (e.g., AVD regimen) to reduce bleomycin reliance and related toxicities.
In sALCL, Brentuximab vedotin has shown remarkable efficacy, especially in cases with high CD30 expression.
Research is exploring combinations with agents like bendamustine and nivolumab.
Biosimilars: Biosimilars of Brentuximab are being developed to facilitate research by providing more accessible and cost-effective alternatives to the reference biologic.

"A biosimilar is a biologic product highly similar to an existing reference biologic, with no clinically meaningful differences in safety, purity, or potency. Biosimilars expand research opportunities by providing accessible alternatives to original biologics."
Benefits include cost-effectiveness, high quality, and support for innovation in ADC development and combination therapies.
Biosimilars are intended for research use only and not for diagnostic or therapeutic applications.